Enhanced anti-cancer effects of intralymphatic aclarubicin on distal lymph node metastases: quantitative evaluation using a new experimental model in mice.
The anti-cancer drug aclarubicin (2.0 mg/kg body weight) was injected into the left popliteal lymph node (the primary draining node of the foot-pad region) or into the tail vein, 8 days after a subcutaneous inoculation of 5 x 10(5) P388 leukemia cells/mouse in the left hind paw foot-pad of mouse (donor). During this time, metastases were established in the lower para-aortic nodes (the secondary draining nodes of this region). On day 10, the lower para-aortic nodes taken from each donor were transferred intraperitoneally to a normal mouse (recipient). From the recipients' survival time, the viable P388 leukemia cell number in the para-aortic nodes per donor mouse was estimated with a calibration line. The recipients' survival curve in the intralymphatic chemotherapy group was statistically significantly better than that in the intravenous chemotherapy group.
Hagiwara
A
A
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Takahashi
T
T
Sawai
K
K
Seiki
K
K
Ito
M
M
Sakakura
C
C
Shobayashi
S
S
D015250:Aclarubicin / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002138:Calibration; D004195:Disease Models, Animal; D005260:Female; D007272:Injections, Intralymphatic; D007941:Leukemia P388 / Q000188:drug therapy* / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D015250:Aclarubicin